Related Experiment Video
Updated: Nov 3, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
Alessandro Noto1, Ramona Cassin1, Veronica Mattiello2
1Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Insights
Autoimmune cytopenias (AICs) in chronic lymphocytic leukemia (CLL) often require treatment beyond corticosteroids. BTK inhibitors show promise for managing AICs in CLL by rebalancing the immune system.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Autoimmune cytopenias (AICs) are frequent complications in chronic lymphocytic leukemia (CLL), with autoimmune hemolytic anemia (AIHA) being the most common.
- Corticosteroid-refractory AICs necessitate CLL-directed treatment according to iwCLL guidelines.
- Traditional chemo-immunotherapy yields variable results for AICs in CLL, with limited data on novel agents.
Purpose of the Study:
- To review the efficacy and safety of novel agents for treating autoimmune cytopenias (AICs) in chronic lymphocytic leukemia (CLL).
- To evaluate the role of Bruton's tyrosine kinase (BTK) inhibitors, BCL-2 inhibitors, and other novel agents in managing AICs associated with CLL.
Main Methods:
- Literature review and analysis of current evidence regarding novel therapeutic agents for AICs in CLL.
- Discussion of the immunological mechanisms of action for agents like ibrutinib and venetoclax in the context of CLL-associated autoimmunity.
Main Results:
- Idelalisib use in AICs is controversial, with recommendations to avoid it in this setting.
- Ibrutinib demonstrates rapid and durable responses in treating AIHA in CLL, attributed to ITK-driven immune rebalancing.
- Evidence for BCL-2 inhibitors (e.g., venetoclax) in CLL-associated AICs is limited, and their use is debated, especially in combination therapies.
Conclusions:
- BTK inhibitors are currently the most suitable treatment option for autoimmune cytopenias in CLL due to their ability to mitigate immune dysregulation.
- Further research is needed to clarify the role of BCL-2 inhibitors and other novel agents in managing AICs in CLL patients.
Abstract:
Autoimmune cytopenias (AICs) have been reported as a common complication in chronic lymphocytic leukemia (CLL) with autoimmune hemolytic anemia (AIHA), accounting for most cases. According to iwCLL guidelines, AICs poorly responsive to corticosteroids are considered indication for CLL-directed treatment. Chemo-immunotherapy has classically been employed, with variable results, and little data are available on novel agents, the current backbone of CLL therapy. The use of idelalisib in the setting of AICs is controversial and recent recommendations suggest avoiding idelalisib in this setting. Ibrutinib, through ITK-driven Th1 polarization of cell-mediated immune response, is known to produce an immunological rebalancing in CLL, which stands as a fascinating rationale for its use to treat autoimmunity. Although treatment-emergent AIHA has rarely been reported, ibrutinib has shown rapid and durable responses when used to treat AIHA arising in CLL. There is poor evidence regarding the role of BCL-2 inhibitors in CLL-associated AICs and the use of venetoclax in such cases is debated. Furthermore, their frequent use in combination with anti-CD20 agents might represent a confounding factor in evaluating their efficacy. In conclusions, because of their ability to mitigate an immunological dysregulation that is (at least partly) responsible for autoimmunity in CLL, to date BTK-inhibitors stand out as the most suitable choice when treatment of autoimmune cytopenias is required.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:27Tumor Immunotherapy
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...